Patent · US Active

Type polypeptide targeting tumours

US10428114B2 · kind B2 · utility

0Cited by

0References

10Claims

0Family size

Assignees

Sichuan University · CN
Yaopharma Co., Ltd. · CN

Inventors

Zhirong Zhang · Nanhu, CN
Tao Gong · Beijing, CN
Yan Zhang · Fort Washington, US
Xu SONG · Sichuan, CN
Tijia CHEN · Sichuan, CN
Yao Fu · Lo Wu, CN
Xun Sun · Jinan, CN
Xiaoqing BAI · Chongqing, CN
Bei Zhang · Chesterfield, US

Key dates

Filing date	Sep 30, 2016
Grant date	Oct 1, 2019
Priority date	—
Expiry date	Sep 30, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided is a nRGD polypeptide formed by connecting alanine-alanine-asparagine (AAN) and a polypeptide containing arginine-glycine-aspartic acid (RGD), wherein the nRGD polypeptide can target tumor vessels, tumor cells and tumor-associated macrophages, and mediate the targeted delivery of tumors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.